Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands

Muhammad Altaf; M. Monim-Ul-Mehboob; Adam A.A. Seliman; Manzar Sohail; Mohammed I.M. Wazeer; Anvarhusein A. Isab; L. Li; V. Dhuna; G. Bhatia; K. Dhuna

doi:10.1016/j.ejmech.2015.03.019

Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands

Muhammad Altaf
, M. Monim-Ul-Mehboob
, Adam A.A. Seliman
, Manzar Sohail
, Mohammed I.M. Wazeer
, Anvarhusein A. Isab^*
, L. Li
, V. Dhuna
, G. Bhatia
, K. Dhuna

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Two new gold(I) complexes that contain tri-ter-butylphosphine and dialkyl dithiocarbamate ligands were synthesized and characterized by FTIR, NMR spectroscopy, Cyclic voltammetry, elemental analysis and X-ray diffraction. The in vitro cytotoxicity of both complexes was examined against A549 (lung cancer), MCF7 (breast cancer), and HeLa (cervical cancer) human cancer cell lines. Both complexes exhibit very strong in vitro cytotoxic effects against A549, MCF7 and HeLa cell lines. The screening of the cytotoxic activity based on IC₅₀ data against the A549, MCF7, and HeLa lines shows that the synthesized gold(I) complexes are highly effective, particularly against HeLa cancer cell line. Based on IC₅₀ data, the cytotoxic activity of both complexes is better than well-known commercial anticancer drug cisplatin against all the three cancer lines tested.

Original language	English
Pages (from-to)	464-472
Number of pages	9
Journal	European Journal of Medicinal Chemistry
Volume	95
DOIs	https://doi.org/10.1016/j.ejmech.2015.03.019
State	Published - 5 May 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Masson SAS.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anticancer activity
Gold(I) complexes
Human A549
MCF7 and HeLa cell lines

ASJC Scopus subject areas

Pharmacology
Drug Discovery
Organic Chemistry

Access to Document

10.1016/j.ejmech.2015.03.019

Cite this

Altaf, M., Monim-Ul-Mehboob, M., Seliman, A. A. A., Sohail, M., Wazeer, M. I. M., Isab, A. A., Li, L., Dhuna, V., Bhatia, G., & Dhuna, K. (2015). Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands. European Journal of Medicinal Chemistry, 95, 464-472. https://doi.org/10.1016/j.ejmech.2015.03.019

@article{16821a9db0684687b9e205fe10b70f41,

title = "Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands",

abstract = "Two new gold(I) complexes that contain tri-ter-butylphosphine and dialkyl dithiocarbamate ligands were synthesized and characterized by FTIR, NMR spectroscopy, Cyclic voltammetry, elemental analysis and X-ray diffraction. The in vitro cytotoxicity of both complexes was examined against A549 (lung cancer), MCF7 (breast cancer), and HeLa (cervical cancer) human cancer cell lines. Both complexes exhibit very strong in vitro cytotoxic effects against A549, MCF7 and HeLa cell lines. The screening of the cytotoxic activity based on IC50 data against the A549, MCF7, and HeLa lines shows that the synthesized gold(I) complexes are highly effective, particularly against HeLa cancer cell line. Based on IC50 data, the cytotoxic activity of both complexes is better than well-known commercial anticancer drug cisplatin against all the three cancer lines tested.",

keywords = "Anticancer activity, Gold(I) complexes, Human A549, MCF7 and HeLa cell lines",

author = "Muhammad Altaf and M. Monim-Ul-Mehboob and Seliman, \{Adam A.A.\} and Manzar Sohail and Wazeer, \{Mohammed I.M.\} and Isab, \{Anvarhusein A.\} and L. Li and V. Dhuna and G. Bhatia and K. Dhuna",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Masson SAS.",

year = "2015",

month = may,

day = "5",

doi = "10.1016/j.ejmech.2015.03.019",

language = "English",

volume = "95",

pages = "464--472",

journal = "European Journal of Medicinal Chemistry",

issn = "0223-5234",

publisher = "Elsevier Masson s.r.l.",

}

Altaf, M, Monim-Ul-Mehboob, M, Seliman, AAA, Sohail, M, Wazeer, MIM, Isab, AA, Li, L, Dhuna, V, Bhatia, G & Dhuna, K 2015, 'Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands', European Journal of Medicinal Chemistry, vol. 95, pp. 464-472. https://doi.org/10.1016/j.ejmech.2015.03.019

TY - JOUR

T1 - Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands

AU - Altaf, Muhammad

AU - Monim-Ul-Mehboob, M.

AU - Seliman, Adam A.A.

AU - Sohail, Manzar

AU - Wazeer, Mohammed I.M.

AU - Isab, Anvarhusein A.

AU - Li, L.

AU - Dhuna, V.

AU - Bhatia, G.

AU - Dhuna, K.

PY - 2015/5/5

Y1 - 2015/5/5

N2 - Two new gold(I) complexes that contain tri-ter-butylphosphine and dialkyl dithiocarbamate ligands were synthesized and characterized by FTIR, NMR spectroscopy, Cyclic voltammetry, elemental analysis and X-ray diffraction. The in vitro cytotoxicity of both complexes was examined against A549 (lung cancer), MCF7 (breast cancer), and HeLa (cervical cancer) human cancer cell lines. Both complexes exhibit very strong in vitro cytotoxic effects against A549, MCF7 and HeLa cell lines. The screening of the cytotoxic activity based on IC50 data against the A549, MCF7, and HeLa lines shows that the synthesized gold(I) complexes are highly effective, particularly against HeLa cancer cell line. Based on IC50 data, the cytotoxic activity of both complexes is better than well-known commercial anticancer drug cisplatin against all the three cancer lines tested.

AB - Two new gold(I) complexes that contain tri-ter-butylphosphine and dialkyl dithiocarbamate ligands were synthesized and characterized by FTIR, NMR spectroscopy, Cyclic voltammetry, elemental analysis and X-ray diffraction. The in vitro cytotoxicity of both complexes was examined against A549 (lung cancer), MCF7 (breast cancer), and HeLa (cervical cancer) human cancer cell lines. Both complexes exhibit very strong in vitro cytotoxic effects against A549, MCF7 and HeLa cell lines. The screening of the cytotoxic activity based on IC50 data against the A549, MCF7, and HeLa lines shows that the synthesized gold(I) complexes are highly effective, particularly against HeLa cancer cell line. Based on IC50 data, the cytotoxic activity of both complexes is better than well-known commercial anticancer drug cisplatin against all the three cancer lines tested.

KW - Anticancer activity

KW - Gold(I) complexes

KW - Human A549

KW - MCF7 and HeLa cell lines

UR - https://www.scopus.com/pages/publications/84964296353

U2 - 10.1016/j.ejmech.2015.03.019

DO - 10.1016/j.ejmech.2015.03.019

M3 - Article

C2 - 25841201

AN - SCOPUS:84964296353

SN - 0223-5234

VL - 95

SP - 464

EP - 472

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

ER -

Synthesis, characterization and anticancer activity of gold(I) complexes that contain tri- tert -butylphosphine and dialkyl dithiocarbamate ligands

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this